Multiparametric MRI prostate cancer screening, MRI-guided biopsy, and laser focal therapy treatment.
Improved detection through advanced imaging, geneomic analysis, and biomarker screening.
Combining next-generation imaging technology and genomic analysis to deliver truly personalized care.
Advanced imaging, preventative care, and diagnostic services provided across all HALO Dx centers.
Your Health Is Personal
Healthcare services should be tailored to your specific needs. To get the care and treatment that is right for you, you and your doctor need to have a clear and detailed picture of your overall health. One-off tests and one-size-fits-all diagnostics cannot provide that. Personalized care requires an integrated approach. At HALO Dx, we're developing next-generation AI technology to do just that. We use advanced imaging modalities, genomics, biomarker analysis, and more to provide a holistic picture of your wellbeing.
We believe that more knowledge means more power when it comes to making decisions about your care and treatment. We are doctors, nurses, engineers, scientists, and researchers on a mission to shape a better future for healthcare by improving individual outcomes, one patient at a time.
Diagnostics designed for you.
One Size Does Not Fit All
Diseases like cancer, dementia and cardiovascular disease are complex and can be caused by a combination of genetic, environmental, and lifestyle factors.
Make It Personal
Comprehensive diagnostics will change the way we prevent, diagnose, and treat diseases. The HALO Diagnostics platform makes sense of the complex to personalize your health journey.
With medical imaging, doctors can see a clear picture of what is happening in your body.
Molecular diagnostics provide a different kind of picture, a view of what is happening within the machinery of your cells.
We combine both, using deep learning, for the clearest and most comprehensive view of your health.
PRECISION DIAGNOSTIC ENSEMBLE
Prostate Cancer Screening
A recent study published in the Journal of Urology demonstrated the power of combining liquid biomarkers and magnetic resonance imaging (MRI) in prostate cancer screening.1
Clinically significant prostate cancer missed by the best performing liquid biomarker test alone.
Clinically significant prostate cancer missed when the liquid biomarker test was combined with MRI.
committed to progress
Laser Focal Therapy for Prostate Cancer
Dr. John Feller, Chief Medical Officer at HALO Diagnostics, recently presented 10-year results from our phase II clinical trail of laser focal therapy for prostate cancer. The results are impressive.2
Prostate cancer survival rate.
Incontinence compared to over 25% risk with whole gland prostatectomy.
Erectile dysfunction compared to ~50% with whole gland prostatectomy.
Infection compared to 4% with whole gland prostatectomy.
Dr. John Feller
In the News
HALO Diagnostics Expands Radiation-Free, Minimally Invasive Prostate Cancer Treatment to Imaging Centers NationwideRead Article
Tech Crunch: With $19M A round, Halo Dx combines data streams to better diagnose cancers, dementia and moreRead Article
HALO Diagnostics Among First to Offer PSMA-Targeted PET Imaging for Men with Prostate CancerRead Article
HALO Diagnostics Launches Subtle Medical's Suite of AI-powered Imaging Technologies for Better Patient CareRead Article
ADVANCES IN DIAGNOSING AND TREATING PROSTATE CANCER
We’ve been growing and developing our men’s healthcare program to offer an ensemble of the very latest diagnostic tools, genetic tests, and therapies for more than a decade. For an in-depth guide to understanding the evolution of our prostate care pathway, click below.
1. de la Calle CM, Fasulo V, Cowan JE, et al. Clinical Utility of 4Kscore®, ExosomeDx™ and Magnetic Resonance Imaging for the Early Detection of High Grade Prostate Cancer [published online ahead of print, 2020 Sep 8]. J Urol.
2. John Feller, Bernadette Greenwood, Wes Jones, Rob Toth, Steve Gunberg, and Jeffrey Herz. Outpatient Trans-Rectal MR-Guided Laser Focal Therapy Phase II Clinical Trial: Ten-Year Interim Results. PD17. 2020, April 1. J Urol.